Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies
Status:
Completed
Trial end date:
2020-06-04
Target enrollment:
Participant gender:
Summary
The purpose of this study of MCS110 with PDR001 was to characterize the safety, tolerability,
pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the combination of
MCS110 with PDR001 in adult patients with solid tumors.